Generic Votrient Availability

Votrient is a brand name of pazopanib, approved by the FDA in the following formulation(s):

VOTRIENT (pazopanib hydrochloride - tablet;oral)

  • Manufacturer: GLAXOSMITHKLINE
    Approval date: October 19, 2009
    Strength(s): EQ 200MG BASE [RLD], EQ 400MG BASE

Has a generic version of Votrient been approved?

No. There is currently no therapeutically equivalent version of Votrient available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Votrient. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pyrimidineamines as angiogenesis modulators
    Patent 7,105,530
    Issued: September 12, 2006
    Inventor(s): Boloor; Amogh & Cheung; Mui & Davis; Ronda & Harris; Philip Anthony & Hinkle; Kevin & Mook, Jr.; Robert Anthony & Stafford; Jeffery Alan & Veal; James Marvin
    Assignee(s): SmithKline Beecham Corporation
    Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
    Patent expiration dates:
    • October 19, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pyrimidineamines as angiogenesis modulators
    Patent 7,262,203
    Issued: August 28, 2007
    Inventor(s): Boloor; Amogh & Cheung; Mui & Davis; Ronda & Harris; Philip Anthony & Hinkle; Kevin & Mook, Jr.; Robert Anthony & Stafford; Jeffery Alan & Veal; James Marvin
    Assignee(s): SmithKline Beecham Corporation
    Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
    Patent expiration dates:
    • December 19, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Chemical compounds
    Patent 8,114,885
    Issued: February 14, 2012
    Inventor(s): Boloor; Amogh & Cheung; Mui & Harris; Philip Anthony & Hinkle; Kevin & Stafford; Jeffery Alan & Veal; James Marvin
    Assignee(s): GlaxoSmithKline LLC
    Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
    Patent expiration dates:
    • December 19, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 19, 2014 - NEW CHEMICAL ENTITY
    • April 26, 2015 - TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
    • April 26, 2019 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web3)